| 0.2031 0 (0%) | 05-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.14 | 1-year : | 0.24 |
| Resists | First : | 0.12 | Second : | 0.2 |
| Pivot price | 0.11 |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0.08 |
MA(20) : | 0.12 |
| MA(100) : | 0.89 |
MA(250) : | 3.81 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 29.5 |
D(3) : | 36 |
| RSI | RSI(14): 29.5 |
|||
| 52-week | High : | 23.79 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ATNX ] has closed below the lower bollinger band by 28.1%. Bollinger Bands are 82.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 32 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0 - 0 | 0 - 0 |
| Low: | 0 - 0 | 0 - 0 |
| Close: | 0 - 0 | 0 - 0 |
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
Fri, 19 May 2023
Athenex to lay off 123 WNY employees, close both Buffalo-area plants by mid-August - WGRZ.com
Mon, 15 May 2023
Athenex stock falls after bankruptcy filing (NASDAQ:ATNX) - Seeking Alpha
Mon, 15 May 2023
Athenex Voluntarily Filed For Chapter 11 Proceedings, Shares Plunge - Yahoo Finance
Sun, 14 May 2023
Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process - GlobeNewswire
Wed, 10 May 2023
Athenex gave its 503B business, 50 employees to Pine Pharmaceuticals - Buffalo Business First - The Business Journals
Mon, 20 Mar 2023
Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 6.5e+006 (%) |
| Held by Institutions | 9.7 (%) |
| Shares Short | 415 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.181e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -100.6 % |
| Operating Margin | -72.1 % |
| Return on Assets (ttm) | -19.7 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 1.0282e+008 % |
| Gross Profit (p.s.) | 82.14 |
| Sales Per Share | 686.86 |
| EBITDA (p.s.) | 1.97778e+007 |
| Qtrly Earnings Growth | -10.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -75 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 356330 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|